Plavix

Plavix prevents formation of blood clots and is prescribed to reduce the risk of circulation problems, stroke and heart attack.

Product dosage: 75mg
Package (num)	Per pill	Price	Buy
60	0.99 $	59.67 $ (0%)	🛒 Add to cart
90	0.94 $	89.50 $ 84.24 $ (6%)	🛒 Add to cart
120	0.91 $	119.34 $ 108.81 $ (9%)	🛒 Add to cart
180	0.87 $	179.01 $ 156.78 $ (12%)	🛒 Add to cart
270	0.84 $	268.51 $ 228.15 $ (15%)	🛒 Add to cart
360	0.84 $ Best per pill	358.02 $ 300.69 $ (16%)	🛒 Add to cart
Synonyms Algilis Anclog Anlet Antiplaq Antiplar Apo clopidogrel Areplex Artevil Atelit Ateplax Cirgrel Clavix Clocardigel Clodian Clognil Clopact Clopiboses Clopicard Clopid Clopidix Clopidogrelum Clopidolut Clopigamma Clopigrel Clopilet Clopisan Clopistad Clopivas Clopix Clorel Clorix Clovexil Clovix Dapixol Darxa Dclot Deplatt Diloxol Dopivix Dorel Duocover Duoplavin Expansia Farcet Flusan Globel Greligen Grepid Heart-free Infartan Iscover Karum Klopidogrel Leril Lopirel Nabratin Narutis Nefazan Niaclop Noclog Noklot Odrel Panagrel Pidocar Pidogrel Pigrel Pladex Pladogrel Plagerine Plagril Plagrin Planor Platfree Plavigrel Pleyar Preclot Ravalgen Replet Rokulan Subarcan Terotrom Themigrel Tisten Troken Trombex Vaclo Zillt Zyllt

Plavix (clopidogrel bisulfate) is a prescription antiplatelet medication designed to reduce the risk of heart attack and stroke in patients with specific cardiovascular conditions. It works by preventing platelets in the blood from sticking together and forming dangerous clots. This medication is a cornerstone in the management of atherothrombotic events, offering a targeted mechanism of action that has been validated in extensive clinical trials. Proper use under medical supervision can significantly improve long-term cardiovascular outcomes for at-risk individuals.

Features

• Active ingredient: Clopidogrel bisulfate
• Available in 75 mg and 300 mg oral tablets
• Prodrug requiring hepatic activation via CYP2C19 enzyme
• Once-daily dosing regimen for maintenance therapy
• Brand and generic formulations available
• Coated tablet for ease of swallowing

Benefits

• Reduces the risk of myocardial infarction in patients with recent MI, stroke, or established peripheral arterial disease
• Decreases the likelihood of stent thrombosis in patients with coronary stents
• Lowers the incidence of ischemic stroke in high-risk patients
• Provides predictable platelet inhibition when metabolized properly
• Offers convenient once-daily dosing for improved adherence
• Has demonstrated mortality benefit in acute coronary syndrome patients

Common use

Plavix is primarily indicated for the reduction of atherothrombotic events in patients with acute coronary syndrome (unstable angina/non-Q-wave MI), including those who are to be managed medically and those who are to undergo percutaneous coronary intervention (with or without stent placement). It is also approved for use in recent MI, recent stroke, or established peripheral arterial disease. The medication is typically prescribed as part of a comprehensive cardiovascular risk reduction strategy that may include aspirin therapy (dual antiplatelet therapy), statins, and lifestyle modifications.

Dosage and direction

The standard maintenance dose of Plavix is 75 mg once daily with or without food. For patients with acute coronary syndrome, a loading dose of 300 mg is typically administered, followed by 75 mg daily. In some clinical scenarios, particularly for patients undergoing PCI, a 600 mg loading dose may be used. The duration of therapy varies based on clinical indication, with current guidelines recommending 12 months of dual antiplatelet therapy after drug-eluting stent placement or acute coronary syndrome, though duration may be individualized based on bleeding and thrombotic risk assessment.

Precautions

Patients should be monitored for signs of bleeding throughout therapy. Genetic testing for CYP2C19 poor metabolizer status should be considered, as reduced effectiveness has been observed in these patients. Caution is advised in patients who may require urgent coronary artery bypass graft surgery. Regular assessment of hepatic function is recommended. Patients should be advised that it may take longer than usual to stop bleeding while taking Plavix, and they should report any unusual bleeding or bruising to their healthcare provider immediately.

Contraindications

Plavix is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. It should not be used in patients with hypersensitivity to clopidogrel or any component of the formulation. The medication is contraindicated in patients with severe hepatic impairment, as the metabolism and activation of the prodrug may be compromised. Use with caution in patients taking other medications that affect hemostasis.

Possible side effect

Common side effects include bleeding manifestations (ecchymosis, epistaxis, hematoma), diarrhea, rash, and pruritus. Serious but less common side effects may include severe bleeding requiring transfusion, thrombotic thrombocytopenic purpura (usually within the first two weeks of therapy), neutropenia/agranulocytosis, and hepatic enzyme elevations. Gastrointestinal hemorrhage occurs in approximately 2% of patients, while intracranial hemorrhage occurs in approximately 0.1-0.4% of patients.

Drug interaction

Significant interactions occur with other antiplatelet agents (aspirin, NSAIDs), anticoagulants (warfarin, direct oral anticoagulants), and SSRIs/SNRIs, which may increase bleeding risk. Proton pump inhibitors, particularly omeprazole and esomeprazole, may reduce Plavix’s effectiveness by inhibiting CYP2C19. Strong CYP2C19 inhibitors (fluconazole, fluvoxamine, felbamate) may reduce the conversion to active metabolite. CYP2C19 inducers (rifampin) may increase antiplatelet effect.

Missed dose

If a dose is missed, patients should take it as soon as they remember unless it is almost time for the next scheduled dose. Patients should not take a double dose to make up for a missed dose. Consistency in dosing is important for maintaining adequate platelet inhibition. If multiple doses are missed, patients should contact their healthcare provider for guidance, as the antiplatelet effect may diminish.

Overdose

Plavix overdose may lead to bleeding complications. There is no specific antidote for clopidogrel overdose. Management should focus on symptomatic treatment and supportive care, including gastric lavage if ingestion was recent. Platelet transfusion may be considered in cases of serious bleeding, though the effectiveness may be limited due to the irreversible nature of platelet inhibition. Monitoring of coagulation parameters and complete blood count is essential.

Storage

Store at room temperature (20-25°C or 68-77°F) in the original container with the lid tightly closed. Keep away from moisture and light. Do not store in bathroom cabinets where humidity levels may fluctuate. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Plavix is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual patient needs may vary, and treatment decisions should be made in consultation with a physician. Always follow the specific instructions provided by your healthcare provider and refer to the official prescribing information for complete details.

Reviews

Clinical trials demonstrate that Plavix reduces the combined risk of ischemic stroke, myocardial infarction, and vascular death in patients with recent stroke, recent MI, or established peripheral arterial disease. The CAPRIE trial showed an overall 8.7% relative risk reduction compared to aspirin. In CURE, clopidogrel plus aspirin versus aspirin alone showed a 20% relative risk reduction in cardiovascular death, MI, or stroke in ACS patients. Real-world evidence supports these findings, though bleeding risk remains a consideration in clinical practice. Patient-reported outcomes generally reflect satisfaction with therapy when balanced against bleeding risk concerns.